Gary J. Nabel is an American virologist and immunologist who has held research positions at the U.S. National Institutes of Health (NIH) and in the biotechnology industry. He was the founding director of the Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID) from 1999 to 2012 and later served as chief scientific officer at Sanofi. He is president and chief executive officer of ModeX Therapeutics, a biotechnology company based in Natick, Massachusetts. He has served as a director of SIGA Technologies since June 2021.
Nabel received a bachelorâÂÂs degree from Harvard University in 1975 and an MDâÂÂPhD from Harvard in 1982. He completed his residency in internal medicine at Brigham and WomenâÂÂs Hospital in 1985, and then undertook postdoctoral research focusing on the transcriptional regulation of HIV gene expression by the transcription factor NF-úB.
From 1987 to 1999, Nabel led a research laboratory at the University of Michigan with support from the Howard Hughes Medical Institute. During this time, he conducted research on gene therapy and transcriptional regulation of cellular and viral gene expression.
In 1999, Nabel was appointed as the founding director of the Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases under the NIH. The VRC focused on laboratory research and clinical trials of vaccines, including 100 studies for vaccine candidates against SARS, Chikungunya, Influenza, and Ebola. Research during Nabel's tenure at the VRC included studies on immune mechanisms of protection against Ebola and the identification of broadly neutralizing antibodies to the CD4 binding site of HIV.
In 2012, Nabel became Chief Scientific Officer at Sanofi. He continued research on neutralizing antibodies against HIV and led studies on antibody-mediated stimulation of CD8 T cells using multi-specific antibodies. In 2020, Nabel co-founded ModeX Therapeutics, a clinical-stage biopharmaceutical company primarily focusing on these multi-specific antibodies. ModeX was acquired by OPKO Health in 2022.
Nabel has held positions on various scientific advisory boards and councils, including Chairman of the Strategic Development and Scientific Advisory Council (SDSAC).
See for citation information.